Axamon, 15 mg/ml 1 ml 10 pcs

Axamon® is a reversible cholinesterase inhibitor and directly stimulates impulse conduction at the neuromuscular synapse and in the central nervous system (CNS) due to blockade of membrane potassium channels. It enhances the effect on smooth muscles not only of acetylcholine but also of adrenaline, serotonin, histamine and oxytocin.

Axamon® has the following pharmacological effects:

– improves and stimulates impulse conduction in the nervous system and neuromuscular transmission;
– improves conduction in the peripheral nervous system, impaired due to trauma, inflammation, exposure to local anesthetics, some antibiotics, potassium chloride, etc.
– increases smooth muscle contractility under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, except for potassium chloride;
– improves memory, inhibits progradient development of dementia.

It does not have teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic action. It does not affect the endocrine system.

Pharmacokinetics

In subcutaneous and intramuscular administration, it is rapidly absorbed. Maximum concentration in blood is reached 25-30 min after administration. Binding with plasma proteins is 40-50%.

The drug is rapidly absorbed into the tissues. It is metabolized in the liver. Excretion of the drug is carried out through the kidneys (mainly by tubular secretion and only 1/3 by glomerular filtration) and extrarenal (through gastrointestinal tract).

The elimination half-life of Axamon® during parenteral administration is 2-3 hours. After parenteral administration 34.8% of the drug dose is excreted unchanged in the urine.

Indications

– Diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathies, myasthenia and myasthenic syndrome of various etiologies;

– CNS diseases: bulbar paralysis and paresis, the recovery period of organic CNS lesions accompanied by motor disorders;

– intestinal atony.

Active ingredient

Composition

Solution for intramuscular and subcutaneous administration 1 ml

active ingredient:

ipidacrine hydrochloride monohydrate (in terms of anhydrous) 15 mg

auxiliary substances:

0.1 M hydrochloric acid solution – to pH 3;

water for injection – to 1 ml

How to take, the dosage

The drug is administered by injection or by injection. Doses and duration of treatment are determined individually depending on the disease severity.
Peripheral nervous system disorders

Mono- and polyneuropathies of various genesis, polyradiculopathies: 5-15 mg in / m or v/m 1-2 times / day, 10-15 days course (in severe cases – up to 30 days); then treatment continues with tablet form of the drug.

Miasthenia gravis and myasthenic syndrome: n/a or v/m 15-30 mg 1-3 times/day with further change to the tablet form. Total course of treatment is 1-2 months. If necessary, the treatment can be repeated several times with a break between courses of 1-2 months.

CNS diseases:

Bulbar paralysis and paresis: n/a or v/m 5-15 mg 1-2 times/day, 10-15 days course; afterwards, if possible switch to tablet form;
Recuperation period of organic CNS lesions accompanied with movement disorders: In/m 10-15 mg 1-2 times/day, the course of up to 15 days; then, if possible, switch to the tablet form.

The treatment and prevention of bowel atony: the initial dose is 10-15 mg 1-2 times/day for 1-2 weeks.

Interaction

There is an increased risk of bradycardia if beta-adrenoblockers were used prior to treatment with Axamon®.

Accelerates the inhibitory effect of local anesthetics, aminoglycosides, potassium chloride on neuromuscular transmission and excitation along the peripheral nerves.

Axamon® may be used in combination with nootropic drugs.

Ethanol increases the side effects of the drug.

Special Instructions

Impact on driving and operating machinery

At the time of treatment, one should refrain from driving a vehicle or operating any other vehicle or machinery, as well as from engaging in potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

Contraindications

– Epilepsy;
– extrapyramidal disorders with hyperkinesias;
– angina pectoris;
– marked bradycardia;
– bronchial asthma;
– mechanical obstruction of the intestine or urinary tract;
– vestibular disorders;
– gastric or duodenal ulcer in the acute stage;
– children under 18 years of age (there are no systematized data on its use in children);
– hypersensitivity to any component of the preparation.

With caution is used in case of gastric and duodenal ulcer, thyrotoxicosis, cardiovascular diseases, obstructive pulmonary diseases in anamnesis or acute respiratory diseases.

Side effects

The frequency of adverse reactions that may occur during use of the drug is given in the following classification: very frequent (>1/10 prescriptions), frequent (1/10-1/100 prescriptions), infrequent (1/100-1/1000 prescriptions), rare (1/1000-1/10 000 prescriptions), very rare (< 1/10 000 prescriptions) and of unknown frequency (frequency cannot be calculated from available data).

Psychiatric disorders: infrequent – somnolence.

Nervous system disorders: infrequent – dizziness, headache, seizures; unspecified frequency – tremor.

An organ of vision: unspecified frequency – miosis.

Heart: frequent – palpitations, bradycardia; unspecified frequency – pain in the chest.

Respiratory system: infrequent – increased bronchial secretion.

Gastrointestinal disorders: frequent – salivation, nausea; infrequent – vomiting; rare – diarrhea, epigastric pain.

Liver and biliary tract disorders: unspecified frequency – jaundice.

Skin and subcutaneous tissues: infrequent – itching, rash.

General disorders and disorders at the place of administration: frequent – increased sweating; infrequent – general weakness; unspecified frequency – hypothermia.

Salivation and bradycardia can be reduced by m-cholinoblockers (including atropine, cyclodol, methacin).

In case of itching or rash, the drug should be discontinued. In other cases, the dose is reduced or the drug is interrupted for a short time (1-2 days).

Overdose

Symptoms: decreased appetite, bronchospasm, lacrimation, increased sweating, constriction of pupils, nystagmus, increased GI peristalsis, spontaneous defecation and urination, vomiting, jaundice, bradycardia, intracardiac conduction disorders, arrhythmias, lower blood pressure, anxiety, agitation, fear, ataxia, seizures, coma, speech disorders, sleepiness and general weakness.

Treatment: Use m-cholinoblockers (including atropine, cyclodol, methacin), symptomatic therapy.

Pregnancy use

The use of the drug increases uterine tone and may lead to premature labor, therefore, ipidacrine is contraindicated in pregnancy.

There are no data on the use of the drug during breastfeeding.

Similarities